Holen Sie sich die Stockscreener-App
37.40
0.53%
-0.20
Handel nachbörslich:
37.34
-0.06
-0.16%
Schlusskurs vom Vortag:
$37.60
Offen:
$37.7
24-Stunden-Volumen:
1.61M
Relative Volume:
0.73
Marktkapitalisierung:
$5.03B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-237.54M
KGV:
-14.94
EPS:
-2.5033
Netto-Cashflow:
$-145.05M
1W Leistung:
+3.40%
1M Leistung:
-3.86%
6M Leistung:
+80.85%
1J Leistung:
+0.00%
1-Tages-Spanne:
$36.86
$38.14
1-Wochen-Bereich:
$35.51
$39.10
52-Wochen-Spanne:
$14.62
$49.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
Firmenname
Definium Therapeutics Inc
Sektor
Branche
Telefon
212-220-6633
Adresse
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
37.40 | 4.86B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | Stifel | Buy |
| 2026-04-10 | Eingeleitet | Piper Sandler | Overweight |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-30 | Eingeleitet | Jefferies | Buy |
| 2025-10-13 | Eingeleitet | Needham | Buy |
| 2025-08-04 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-01-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-07-24 | Eingeleitet | ROTH MKM | Buy |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-12-09 | Fortgesetzt | ROTH Capital | Buy |
| 2022-11-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-26 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Eingeleitet | ROTH Capital | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Definium Therapeutics Inc Aktie (DFTX) Neueste Nachrichten
Form 4 Definium Therapeutics Inc For: 29 September By Investing.com - Investing.com South Africa
Definium Therapeutics Insider Sold Shares Worth $1,153,784, According to a Recent SEC Filing - marketscreener.com
Definium Therapeutics CEO Robert Barrow sells $1.15 million in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CMO Daniel Karlin sells $396,894 in stock By Investing.com - Investing.com Australia
Definium Therapeutics CMO Daniel Karlin sells $396,894 in stock - Investing.com
Definium Therapeutics CEO Robert Barrow sells $1.15 million in shares - Investing.com
Definium therapeutics CFO Brandi Roberts sells $123,496 in shares By Investing.com - Investing.com Nigeria
Definium Therapeutics CCO Matthew Wiley sells $113,257 in common shares - Investing.com
To cover stock-grant taxes, Definium Therapeutics (DFTX) legal chief sells 14,051 shares. - Stock Titan
Preferred dividends of Definium Therapeutics, Inc. – HAN:MMQ0 - TradingView
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
Form 4 Definium Therapeutics Inc For: 27 September By Investing.com - Investing.com Canada
Form 144 DEFINIUM THERAPEUTICS For: 26 September - Investing.com India
Form 144 DEFINIUM THERAPEUTICS For: 25 September By Investing.com - Investing.com Nigeria
An officer sold 2,867 shares in the prior three months and lists 3,097 for sale at Definium Therapeutics (DFTX). - Stock Titan
After selling 3,013 shares in June, a Definium Therapeutics (DFTX) officer proposes selling 3,377. - Stock Titan
After selling 13,008 shares in June, Definium Therapeutics (DFTX) officer Mark Sullivan proposes to sell 14,051. - Stock Titan
After selling 10,035 shares in June, a Definium Therapeutics (DFTX) officer proposes another sale. - Stock Titan
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $66 to $91 - Moomoo
DFTX : Definium Therapeutics, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression - Yahoo Finance
Definium Therapeutics, Inc. (DFTX) Options ChainYahoo Finance - Yahoo! Finance Canada
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Definium Therapeutics at TD Cowen summit: phase iii data lift dt120 - Investing.com
Definium Therapeutics reports 5.1‑point gap in second Phase 3 anxiety study - Mugglehead Investment Magazine
Definium Therapeutics, Inc. (DFTX) Latest Stock News & Headlines - Yahoo Finance
Definium Therapeutics, Inc. (DFTX) latest stock news and headlines - Yahoo Finance Singapore
Definium Therapeutics, Inc. (NASDAQ: DFTX) Stock Price, News & Analysis - kalkine.ca
Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX) - The Globe and Mail
Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study - Yahoo Finance
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $78 - Moomoo
Director at Definium Therapeutics (DFTX) now holds 22,296 shares - Stock Titan
Director boosts Definium (DFTX) stake with option exercise - Stock Titan
Definium Reports Second Phase III Success in Anxiety Disorder Program - The Globe and Mail
Definium Therapeutics (DFTX) Stock May Trade At A Premium Despite Phase 3 DT120 Results - Yahoo Finance
Why Definium Therapeutics (DFTX) Is Up 5.7% After Second Positive Phase 3 DT120 Anxiety Trial Result - Yahoo Finance
Definium Therapeutics (DFTX) After Its Phase 3 Win Still Looks Undervalued - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and Definium Therapeutics (DFTX) - theglobeandmail.com
Definium Therapeutics Jumps 20% After Third Phase 3 Win for LSD-Based Anxiety Drug - finance.biggo.com
Stifel raises Definium Therapeutics stock price target on trial win By Investing.com - Investing.com Nigeria
Definium Therapeutics Rises as Investors Weigh Recent Regulatory Momentum and Near-Term Data Catalysts - Quiver Quantitative
Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy' - Benzinga
Definium (DFTX) CEO awarded 750,000 shares tied to clinical milestones - Stock Titan
Definium Therapeutics (DFTX) awards 125K performance shares tied to 2028 milestones - Stock Titan
Definium Therapeutics reports positive Phase 3 Panorama topline: DT120 ODT 100 µg shows -5.1 HAM-A benefit - TradingView
Definium Therapeutics (DFTX) posts third positive Phase 3 anxiety result ahead of planned NDA submission - Stock Titan
Definium Therapeutics stock jumps on positive trial results By Investing.com - Investing.com Nigeria
Definium Therapeutics stock jumps on positive trial results - Investing.com
S&P 500 Futures Decline in Premarket Trading; Definium Therapeutics, Primo Brands Lead - Barron's
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder - Business Wire
Finanzdaten der Definium Therapeutics Inc-Aktie (DFTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Definium Therapeutics Inc-Aktie (DFTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Barrow Robert | Chief Executive Officer |
Sep 25 '26 |
Sale |
36.57 |
31,550 |
1,153,784 |
2,213,090 |
| Wiley Matthew T. | Chief Commercial Officer |
Sep 25 '26 |
Sale |
36.57 |
3,097 |
113,257 |
359,036 |
| Sullivan Mark | Chief Legal Officer |
Sep 25 '26 |
Sale |
36.57 |
14,051 |
513,845 |
494,228 |
| Roberts Brandi | Chief Financial Officer |
Sep 25 '26 |
Sale |
36.57 |
3,377 |
123,497 |
394,528 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):